Navigation Links
Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization

Proprietary technology identifies small molecule JAK2 and Pim kinase


SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced data as part of a series of presentations at the 2007 AACR-NCI-EORTC International Conference that describe how its proprietary CLIMB technology was used in lead development and design of small molecule JAK2 and Pim kinase inhibitors (Posters C200 and C208).

Poster C200 (Abstract No. 907)

Effect of small molecule inhibitors of JAK2 kinase on modulating signaling cascades downstream of cytokine receptors

Janus kinases (JAKs) are critical to a number of intracellular signaling pathways. Dysregulation of JAK2 signaling has been implicated in myoproliferative disorders, leukemia, lymphoma and various solid tumors. Utilizing CLIMB, SuperGen's proprietary technology, scientists used a JAK2 crystal structure to build several models that were made into a substrate for screening a large, virtual small molecule library. This process generated a subset of leads that were screened using in silico algorithms to identify "druggable" candidates to pursue.

Poster C208 (Abstract No. 985)

A small molecule inhibitor of Pim-1 kinase with activity in both hematological and solid tumor malignancies

Pim-1 kinase is involved in signaling pathways as a potent inhibitor of programmed cell death (apoptosis). Pim-1 is over expressed in many cancer types, including AML, CML, bladder and oral cancers. Scientists used SuperGen's CLIMB technology to build a model that allowed for the prediction of small molecule inhibitors. Leads were screened to identify those with inhibitory activity with low nanomolar IC50 concentrations. Data support further development of the lead compounds in liquid and solid tumors.

Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site

"With our CLIMB technology we are able to decrease cycle times while identifying the most druggable candidates," said Dr. James S. Manuso, President and Chief Executive Officer. "This allows us to move at a rapid pace to select candidates that can be advanced into clinical trials."

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.


Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Manager, Investor Relations

Business Development Tel: (925) 560-2845

Tel: (925) 560-0100 E-mail:


SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
5. President Bush Ignores Americas Plea for Support of Stem Cell Research
6. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
7. Diabetes drug supported by Mexican Diabetes Federation
8. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
11. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... 25, 2015  Linden Care, LLC, a retail specialty ... for patients suffering from chronic pain, said today that ... Restraining Order (TRO) enjoining Express Scripts from unilaterally terminating ... --> --> The company ... legal options. --> --> ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... Intellitec Solutions announced today that they have ... as Microsoft’s official group for end users of Dynamics SL ERP software, the ... experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to the ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... Ashburn, VA (PRWEB) , ... November 26, 2015 ... ... Planners, an American Express Travel Representative. As a franchise owner, Somu now offers ... range of cruise, destination wedding packages, private cruise sales, as well as, cabin ...
(Date:11/26/2015)... ... 2015 , ... WorldCare International, Inc., the first company to ... Benefits Conference. The Employee Benefits Conference was hosted by the International Foundation of ... 2015. The conference was held at the Hawaii Convention Center in Honolulu, Oahu, ...
Breaking Medicine News(10 mins):